Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials

References

• Lindstrom E , Eberhard J , Neovius M , Levander S . Costs of schizophrenia during 5 years. Acta Psychiatr Scand Suppl. 2007; 116(435): 33–40.
   Google Scholar
• Lieberman JA , Perkins D , Belger A , Chakos M , Jarskog F , Boteva K et al. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001; 50(11): 884–97.
   Google Scholar
• van Os J , Kapur S . Schizophrenia. Lancet. 2009; 374(9690): 635–45.
   Google Scholar
• McGrath J , Saha S , Chant D , Welham J . Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008; 30: 67–76.
   Google Scholar
• Knapp M , Mangalore R , Simon J . The global costs of schizophrenia. Schizophr Bull. 2004; 30(2): 279–93.
   Google Scholar
• Hasan A , Falkai P , Wobrock T , Lieberman J , Glenthoj B , Gattaz WF et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013; 14(1): 2–44.
   Google Scholar
• Stahl SM , Morrissette DA , Citrome L , Saklad SR , Cummings MA , Meyer JM et al. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013; 18(3): 150–62.
   Google Scholar
• Zygmunt A , Olfson M , Boyer CA , Mechanic D . Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002; 159(10): 1653–64.
   Google Scholar
• Valenstein M , Ganoczy D , McCarthy JF , Myra Kim H , Lee TA , Blow FC . Antipsychotic adherence over time among patients receiving treatment for schizophrenia: A retrospective review. J Clin Psychiatry. 2006; 67(10): 1542–50.
   Google Scholar
• Keith SJ , Kane JM . Partial compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psychiatry. 2003; 64(11): 1308–15.
   Google Scholar
• Caseiro O , Perez-Iglesias R , Mata I , Martinez-Garcia O , Pelayo-Teran JM , Tabares-Seisdedos R et al. Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. J Psychiatr Res. 2012; 46(8): 1099–105.
   Google Scholar
• Perkins DO , Johnson JL , Hamer RM , Zipursky RB , Keefe RS , Centorrhino F et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006; 83(1): 53–63.
   Google Scholar
• Weiden PJ , Kozma C , Grogg A , Locklear J . Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004; 55: 886–91.
   Google Scholar
• Dilla T , Ciudad A , Alvarez M . Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013; 7: 275–84.
   Google Scholar
• Agid O , Foussias G , Remington G . Long-acting injectable antipsychotics in the treatment of schizophrenia: Their role in relapse prevention. Exp Opin Pharmacother. 2010; 11(14): 2301–17.
   PubMed Web of Science ®Google Scholar
• Edwards NC , Locklear JC , Rupnow MF , Diamond RJ . Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005; 23(Suppl 1): 75–89.
   Google Scholar
• Kane JM . Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006; 67(Suppl 5): 9–14. [PubMed Abstract].
   Google Scholar
• Stahl SM . Long-acting injectable antipsychotics: Shall the last be first?. CNS Spectr. 2014; 19(1): 3–5.
   Google Scholar
• Shôn Lewis , Jeffrey Lieberman . CATIE and CUtLASS: can we handle the truth?. The British Journal of Psychiatry. 2008; 192(3): 161–3.
   Web of Science ®Google Scholar
• European Medicines Agency. Summary of opinion: Abilify Maintena (EMA/489804/2013). 2013; London, UK: European Medicines Agency.
   Google Scholar
• FDA. Abilify Maintena Kit (NDA 202971). 2013; Silver Spring, MD: FDA.
   Google Scholar
• Zhang J-P , Gallego JA , Robinson DG , Malhotra AK , Kane JM , Correll CU . Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013; 16(6): 1205–18.
   Google Scholar
• Kishimoto T , Robenzadeh A , Leucht C , Leucht S , Watanabe K , Mimura M et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophr Bull. 2014; 40(1): 192–213.
   Google Scholar
• Fusar-Poli P , Kempton MJ , Rosenheck RA . Efficacy and safety of second-generation long-acting injections in schizophrenia: A meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013; 28(2): 57–66.
   Google Scholar
• Citrome L . A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Exp Opin Pharmacother. 2012; 13(11): 1545–73.
   PubMed Web of Science ®Google Scholar
• Leucht C , Heres S , Kane JM , Kissling W , Davis JM , Leucht S . Oral versus depot antipsychotic drugs for schizophrenia – A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011; 127: 83–92.
   Google Scholar
• NICE NIoCE. The NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. 2009; London: NICE. Updated Edition.
   Google Scholar
• National Institute of Clinical Excellence N. Psychosis and schizophrenia in adults: Treatment and management. NICE clinical guideline 178. 2014; London: NICE.
   Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. 2009; York, UK University of York: Centre for Reviews and Dissemination.
   Google Scholar
• National Institute for Health and Care Excellence. Single technology appraisal (STA). Specification for manufacturer/sponsor submission of evidence. 2012; London, UK: NICE.
   Google Scholar
• Lumley T . Network meta-analysis for indirect treatment comparisons. Stat Med. 2002; 21(16): 2313–24.
   Google Scholar
• Ades AE , Mavranezouli I , Dias S , Welton NJ , Whittington C , Kendall T . Network meta-analysis with competing risk outcomes. Value Health. 2010; 13(8): 976–83.
   Google Scholar
• Hong H , Carlin BP , Shamliyan TA , Wyman JF , Ramakrishnan R , Sainfort F et al. Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons. Med Decis Making. 2013; 33(5): 702–14.
   Google Scholar
• Gelman A , Rubin DB . Inference from iterative simulation using multiple sequences. Stat Sci. 1992; 7: 457–72.
   Google Scholar
• Dias S , Welton NJ , Sutton AJ , Ades AE . NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of randomised controlled trials (last updated March 2013). 2013; London, UK: National Institute for Health and Clinical Excellence.
   Google Scholar
• Liberati A , Altman DG , Tetzlaff J , Mulrow C , Gotzsche PC , Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med. 2009; 151(4): W65–94.
   Google Scholar
• Fleischhacker WW , Gopal S , Lane R , Gassmann-Mayer C , Lim P , Hough D et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012; 15(1): 107–18.
   Google Scholar
• Hough D , Gopal S , Vijapurkar U , Lim P , Morozova M , Eerdekens M . Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res. 2010; 116(2–3): 107–17.
   Google Scholar
• Fleischhacker WW , Sanchez R , Perry PP , Jin N , Peters-Strickland T , Johnson BR et al. Aripiprazole once-monthly for the treatment of schizophrenia: A doubleblind, randomized, non-inferiority study vs. oral aripiprazole. December 2–6, 2012; Hollywood, FL, USA: 51st Annual Meeting of the American College of Neuropsychopharmacology.
   Google Scholar
• Kane JM , Sanchez R , Perry PP , Jin N , Johnson BR , Forbes RA et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012; 73(5): 617–24.
   Google Scholar
• Kane JM , Detke HC , Naber D , Sethuraman G , Lin DY , Bergstrom RF et al. Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010; 167(2): 181–9.
   Google Scholar
• Kane JM , Davis JM , Schooler N , Marder S , Casey D , Brauzer B et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002; 159(4): 554–60.
   Google Scholar
• Fleischhacker WW , Sanchez R , Perry PP , Jin N , Peters-Strickland T , Johnson BR et al. Aripiprazole once-monthly for treatment of schizophrenia: Double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014; 205(2): 135–44.
   Google Scholar
• Kishimoto T , Nitta M , Borenstein M , Kane JM , Correll CU . Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10): 957–65.
   Google Scholar
• Lafeuille MH , Dean J , Carter V , Duh MS , Fastenau J , Dirani R et al. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin. 2014; 30: 1643–55.
   Google Scholar
• Kane JM , Eerdekens M , Lindenmayer JP , Keith SJ , Lesem M , Karcher K . Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003; 160(6): 1125–32.
   Google Scholar
• Kramer M , Litman R , Hough D , Lane R , Lim P , Liu Y et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010; 13(5): 635–47.
   Google Scholar
• Pandina G , Lane R , Gopal S , Gassmann-Mayer C , Hough D , Remmerie B et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(1): 218–26.
   Google Scholar
• Campbell DB , Ebert PJ , Skelly T , Stroup TS , Lieberman J , Levitt P et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry. 2008; 63(1): 32–41.
   Google Scholar
• Kishimoto T , Agarwal V , Kishi T , Leucht S , Kane JM , Correll CU . Relapse prevention in schizophrenia: A systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013; 18(1): 53–66.
   Google Scholar